Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (Nasdaq: MASS) appointed Kola Otitoju as Chief Business & Strategy Officer and granted inducement equity on April 21, 2026. The company awarded 110,193 RSUs and options to buy 146,789 shares at an exercise price of $7.26.
The RSUs vest equally May 1, 2027, May 1, 2028, and May 1, 2029; the option vests 1/3 on May 1, 2027 and the remainder in 24 monthly installments thereafter. Awards were made under the 2026 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
908 Devices (NASDAQ:MASS) will present at the Sidoti Small Cap Conference on Wednesday, March 18, 2026. CEO Kevin J. Knopp and CFO Joe Griffith will deliver a virtual presentation starting at 1:45 p.m. ET and will host investor meetings.
A live audio webcast with slides is available via the conference link, and an archived webcast will be posted in the company’s Investors section at www.908devices.com.
908 Devices (Nasdaq: MASS) reported Q4 2025 revenue of $17.4M (+21% YoY) and full-year 2025 revenue of $56.2M (+18% YoY). Recurring revenue was $19.5M (35% of 2025). Q4 delivered GAAP gross margin 53% and positive Adjusted EBITDA $0.7M. Cash and marketable securities were $113.0M with no debt. The company provided 2026 revenue guidance of $64.5M–$67.5M (15%–20% growth).
Management cites margin improvements, installed base growth to 3,736 devices, and continuing operational focus following the March 2025 divestiture.
908 Devices (Nasdaq:MASS) will participate in two investor conferences in March with scheduled fireside chats: TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4 at 9:10 a.m. ET and Leerink Global Healthcare Conference on Monday, March 9 at 1:40 p.m. ET.
According to the company, live and archived webcasts will be available in the Investors section of its website at www.908devices.com.
908 Devices (Nasdaq: MASS) will report fourth quarter and full year 2025 financial results before market open on March 3, 2026. Management will host a conference call and webcast at 8:30 a.m. ET, with live audio on the company Investors website and archived replay within 24 hours.
908 Devices (Nasdaq: MASS) announced software enhancements to its handheld MX908 mass spectrometer on February 5, 2026, adding a new TIC Hunter mission mode for hazardous vapor detection and five priority drug targets. The update aims to improve first responder confidence with faster, more focused trace chemical identification.
New drug targets include medetomidine, N-isopropyl butylone, ADB-PINACA, MDMB-BINACA, and bromazolam. The capabilities are available via a software update through the company customer support portal.
908 Devices (NASDAQ:MASS) reported preliminary unaudited results for Q4 and full year 2025: Q4 revenue ~$17.2M (≈20% YoY) and full-year revenue ~$56.0M (≈17% YoY), aligning with the high end of guidance. The company said it turned Adjusted EBITDA positive in Q4 2025. Q4 strength was attributed to U.S. state and local channel outperformance, international ramp of VipIR, and federal/defense sales. Management stated the company simplified its model toward frontline chemical detection and will release audited results and a 2026 outlook later this quarter.
908 Devices (Nasdaq: MASS) reported third quarter 2025 results and reiterated full-year revenue guidance. Year-to-date revenue was $38.8M, up 16% versus prior year. Q3 revenue was $14.0M, down 4% YoY. Recurring revenue was $4.8M (35% of Q3 revenue) and the installed base grew 27% YoY to 3,512 devices. Operational progress improved margins and losses: Adjusted gross margin was 58% (190 bps improvement QoQ) and Adjusted EBITDA loss narrowed to $1.8M, a 53% QoQ improvement. The company ended Q3 with $112.1M cash and no debt. 2025 revenue guidance remains $54.0M–$56.0M, implying 13%–17% growth versus 2024.
908 Devices (Nasdaq: MASS) will participate in two investor conferences in November 2025: a Stifel Healthcare Conference fireside chat on Wed, November 12, 2025 at 8:40 a.m. ET, and a 27th Annual Stephens Investment Conference fireside chat on Thu, November 20, 2025 at 10:00 a.m. CT / 11:00 a.m. ET.
Both sessions will be available via live and archived webcast on the company Investors page at www.908devices.com for interested parties.
908 Devices (Nasdaq: MASS) sold 23 MX908 handheld mass spectrometers to the United States Coast Guard on October 28, 2025, bringing total Coast Guard fielded MX908 units to more than 35.
The MX908 uses high-pressure mass spectrometry (HPMS) to identify trace levels of narcotics, explosives and hazardous chemicals in solids, liquids, vapors and aerosols, supporting Coast Guard narcotics interdiction, hazardous incident response, port security and boarding missions.
The devices aim to give frontline units rapid, on-scene chemical identification to inform safety and operational decisions.